In our Charts of the Week over the last several weeks we have been analyzing the use of unique biomarkers by pharmaceutical companies. We are extending that analysis today with a look at the biomarker discovery activity of pharma companies as compared with the number...
We recently announced a new product developed here at Amplion called BiomarkerEngine™, which is a system that is able to gather biomarker information from large datasets such as clinical trial databases. BiomarkerEngine is built on our proprietary platform called the...
Hello and welcome to the second half of the first Amplion company blog where I mapped out why our team is dedicated to seeing the promise of personalized medicine fully realized. So now I’m going to cover why we believe that 510(k)-style regulation of LDTs...
